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Introduction
The 2019 Coronavirus (2019-nCoV or SARS-CoV-2) 
disease (COVID-19) has rapidly spread across China 
and to the other countries of the world (1,2). Since 
March 2020, COVID-19 has been characterized as a 
pandemic, representing a serious global public 
health emergency. 
Abstract
Introduction: The 2019 Coronavirus disease (COVID-19) has been characterized as a pandemic, representing a serious global public health emer-
gency. Serological tests have been proposed as reliable tools for detecting Coronavirus SARS-CoV-2 antibodies in infected patients, especially for 
surveillance or epidemiological purposes. The aim of this study is to evaluate the agreement between the IgM/IgG rapid assays, based on lateral flow 
immunochromatographic assay, and the fully automated 2019-nCoV IgM and IgG, based on chemiluminescence immunoassay.
Materials and methods: SARS-CoV-2 antibodies were measured with the BIOSYNEX COVID-19 BSS IgM/IgG test (BIOSYNEX, Illkirch-Graffenstaden, 
France) and the MAGLUMI CLIA (IgM and IgG) (SNIBE – Shenzhen New Industries Biomedical Engineering, Shenzhen, China) in 70 serum samples 
from patients with PCR-confirmed diagnosis. The strength of the agreement of the two methods was calculated by using the Cohen Kappa index.
Results: The results showed a good grade of concordance between the two immunoassays with a Cohen’s kappa coefficient of 0.71 (95%CI: 0.54-
0.87) for IgG SARS-CoV-2 antibodies and 0.70 (95%CI: 0.53-0.87) for IgM SARS-CoV-2 antibodies. In addition, the rapid assays BIOSYNEX COVID-19 
BSS for detecting SARS-CoV-2 antibodies showed a positive likelihood ratio (LR) of 10.63 (95%CI: 2.79-40.57) for IgG and a LR of 6.79 (95%CI: 2.93-
15.69) for IgM.
Conclusion: Our results suggest that the immunochromatographic rapid IgM/IgG test and the chemiluminescence IgM and IgG immunoassay have 
a good degree of concordance, suggesting that both could be considered as useful tools for epidemiologic surveillance.
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Among infected patients who may display differ-
ent clinical symptoms, ranging from mild to severe 
conditions, a discrete amount of individuals re-
mains asymptomatic, being a hidden vehicle, 
which spreads infection. Accordingly, the World 
Health Organization (WHO) has stressed the need 
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for research on in vitro rapid and effective screen-
ing test, in order to quickly identify SARS-CoV-2 in-
fected individuals and prevent contagion (3).
To date, the diagnosis of COVID-19 must be con-
firmed by a molecular test using real-time reverse 
transcriptase-polymerase chain (RT-PCR) assay on 
the oropharyngeal or nasopharyngeal swabs for 
detecting 2019-nCoV genome (4). Although RT-
PCR represents the gold standard for COVID-19 di-
agnosis, serological tests are emerging as valid 
tools for identifying infected subjects, especially 
for surveillance or epidemiological purposes (5). 
Although there are many commercially available 
COVID-19 antibody tests, data concerning the per-
formance of these assays are currently limited, and 
many of these tests have been approved for re-
search use only. 
The aim of this study is to compare the BIOSYNEX 
COVID-19 BSS IgM/IgG rapid test (BIOSYNEX, Il-
lkirch-Graffenstaden, France) with the fully auto-
mated MAGLUMI 2019-nCoV IgM and IgG (SNIBE – 
Shenzhen New Industries Biomedical Engineering, 
Shenzhen, China), which we have recently imple-
mented in our laboratory. Given the increased de-
mand for rapid serological tests, its comparison 
with serologically positive or negative results 
measured by CLIA may be helpful in evaluating 




A total of 70 patients with PCR-confirmed COV-
ID-19 diagnosis (41 males and 29 females, median 
age 66 (59-74) years), from April to May 2020, were 
enrolled in this study. For each patient, the serum 
sample was obtained during the hospital stay, 7-10 
days after nasopharyngeal and oropharyngeal 
swabs collection. The SARS-CoV-2 IgM and IgG 
measurement was performed at the Department 
of Laboratory Medicine, University Hospital “P. Gi-
accone”, Palermo, Italy. All samples were analysed 
anonymously. Demographical and clinical data 
were recorded at admission. All the clinical and bi-
ological assessments were carried out in accord-
ance with the Declaration of Helsinki, and the 
study was approved by the local Ethics Commit-
tee. All participants gave written consent. 
Methods
CLIA assay
The MAGLUMI 2019-nCoV IgG/IgM assay is a cap-
ture CLIA for the quantitative measurement of IgM 
and IgG antibodies against SARS-CoV-2 in human 
serum by using the fully automated MAGLUMI an-
alyser (SNIBE – Shenzhen New Industries Biomedi-
cal Engineering, Shenzhen, China). According to 
the manufacturer’s instructions, serum antibodies 
directed against both virus spike (CoV-S) and nu-
cleocapsid (CoV-N) are detected by using magnet-
ic microbeads coated with ABEI-labelled 2019-
nCoV recombinant antigen. As declared by the 
manufacturer, a threshold of positivity of 1.00 AU/
ml was established for both IgM and IgG, whilst 
the overall indicated reproducibility of assays 
ranges from 6.8% to 8.7%. Borderline data (≥ 0.95 
to < 1.0) were considered reactive. 
Immunochromatographic assay
The BIOSYNEX COVID-19 BSS assay (BIOSYNEX, Il-
lkirch-Graffenstaden, France) is a rapid, portable 
qualitative chromatographic assay. The test cas-
sette consists of SARS-CoV-2 recombinant anti-
gens (Spike Protein, as declared by manufacturer) 
conjugated with colloidal gold; a nitrocellulose 
membrane strip containing an IgG line (G Line) 
coated with anti-human IgG, an IgM line (M Line) 
coated with anti-human IgM, and the control line 
(C Line) coated with goat-anti-rabbit IgG. It was 
performed on serum samples according to the 
manufacturer’s instructions. If a line was observed 
for IgM and/or IgG, the test was considered posi-
tive. If the control line did not appear, the test was 
invalidated and repeated. Weak signal for IgM and 
IgG, together or separate, was considered positive. 
Ten serum samples were randomly selected and 
tested six times in order to evaluate the assay re-
peatability. Two independent operators observed 
repeatability of 0.83. Both tests are CE (European 
Community) approved.
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Statistical analysis
Statistical analysis was performed using MedCalc 
Statistical Software version 15.0 (MedCalc Soft-
ware Ltd, Ostend, Belgium; https://www.medcalc.
org; 2015). Sensitivity, specificity, positive predic-
tive value (PPV) and negative predictive value 
(NPV) were calculated. Results were considered 
significant for a P < 0.05. The Cohen Kappa index 
was calculated to determine the strength of the 
agreement of the two methods used. Results were 
interpreted according to the following kappa val-
ues: i) 0.01-0.20, slight agreement; ii) 0.21-0.40, fair 
agreement; iii) 0.41-0.60, moderate agreement; iv) 
0.61-0.80, substantial agreement; and v) 0.81-1.00, 
perfect agreement (6). 
Results 
The results of the comparison between rapid BIO-
SYNEX COVID-19 BSS with the MAGLUMI 2019-
nCoV for SARS-CoV-2 IgM and IgG detection are 
reported in Table 1. 
The comparison between MAGLUMI 2019-nCoV 
positive/negative versus BIOSYNEX COVID-19 BSS 
positive/negative results yielded an overall concord-
ance of 86% for both IgM and IgG detection, with a 
Cohen’s kappa coefficient of 0.71 (95%CI: 0.54-0.87) 
for IgG and 0.71 (95%CI: 0.54-0.87) for IgM. 
Table 1 shows the comparison between the rapid 
test cassette BIOSYNEX and the CLIA MAGLUMI 
IgG/IgM tests. Overall, the rapid test BIOSYNEX 
COVID-19 assay showed good accuracy for SARS-
CoV-2 IgM and IgG detection compared to the MA-
GLUMI 2019-nCoV CLIAs (Table 2). 
MAGLUMI 2019-nCov
SARS-CoV-2 IgM Positive Negative Total
Positive 24 (34%) 5 (7%) 29 (41%)
BIOSYNEX COVID-19 BSS Negative 5 (7%) 36 (51%) 41 (59%)
Total 29 (41%) 41 (59%) 70 (100%)
MAGLUMI 2019-nCov
SARS-CoV-2 IgG Positive Negative Total
Positive 36 (51%) 2 (3%) 38 (54%)
BIOSYNEX COVID-19 BSS Negative 8 (11%) 24 (34%) 32 (46%)
Total 44 (63%) 26 (37%) 70 (100%)
Biosynex Covid-19 BSS 
vs
MAGLUMI 2019-nCov
SARS-CoV-2 IgM SARS-CoV-2 IgG
Sensitivity (95%CI), % 83 (0.64-0.94) 82 (0.67-0.92)
Specificity (95%CI), % 88 (0.74-0.96) 93 (0.75-0.99)
PPV (95%CI) % 83 (0.64-0.94) 95 (0.82-0.99)
NPV (95%CI), % 88 (0.74-0.96) 75 (0.57-0.88)
LR+ (95%CI) 6.79 (2.93-15.69) 10.63 (2.79-40.57)
C-k (95%CI) 0.71 (0.54-0.87) 0.71 (0.54-0.87)
PPV - Positive predictive value. NPV - Negative predictive value. LR - Likelihood ratio. CI - Confidence interval. C-k - Cohen’s kappa.
Table 1. Comparison of rapid BYOSINEX COVID-19 BSS with the MAGLUMI 2019-nCoV for SARS-CoV-2 IgM and IgG detection
Table 2. Accuracy indices for the rapid test BIOSYNEX COVID-19 assay for SARS-CoV-2 IgM and IgG detection compared to the MA-
GLUMI 2019-nCoV CLIA
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Discussion
In the current study, we compared the results of 
the rapid test cassette BIOSYNEX COVID-19 BSS for 
detecting SARS-CoV-2 IgM and IgG with the fully 
automated MAGLUMI 2019-nCoV CLIA, used as the 
reference method. Although the MAGLUMI 2019-
nCoV assay cannot be considered the serological 
gold standard test, its analytical performance has 
been successfully evaluated by Lippi et al. and Pa-
doan et al. (7,8). The authors reported a sensitivity 
of 100% and 88% for detecting SARS-CoV-2 IgG 
and IgM in COVID-19 patients (7,8). 
In the current study, we showed that the BIOSYN-
EX COVID-19 BSS IgM/IgG rapid test cassette is 
congruent with the fully automated MAGLUMI 
2019-nCoV, in detecting SARS-CoV-2 antibodies.
Our findings are in accordance with Hoffman et al. 
(9). Thus, the BIOSYNEX COVID-19 BSS IgM/IgG 
rapid test cassette could be used as a quick tool 
for possible identification of subjects who have 
had exposure to SARS-CoV-2 infection and thus 
developed antibodies. Importantly, the target of 
antibodies detected by BIOSYNEX assay is the viral 
spike protein binding the spike protein’s receptor-
binding domain. As known, any antibody cross-re-
activity between common cold human Coronavi-
rus and SARS-CoV-2 would result in false-positive 
interfering with antibody-based testing and SARS-
CoV-2 surveillance. Scientific evidence suggests 
that the overall specificity of serological assays us-
ing only the nucleocapsid protein is poor, whereas 
assays based on the spike protein are more specif-
ic (10). Unfortunately, the type of antigen/s is often 
not reported by in vitro diagnostics companies 
making difficult to understand whether antibodies 
detected with different assays have a neutralizing 
effect on the virus. Noteworthy, serum IgM and 
IgG detection should not be considered as an al-
ternative but as a complementary tool to molecu-
lar analysis, providing different clinical information 
on SARS-CoV-2 infection. While molecular tests al-
low to directly detecting the virus in the body, se-
rological tests assess the body’s immune response 
to the infection caused by the virus.
Serological tests are useful potential tools for the 
rapid screening population, helping to prevent 
contagion. They are important for activating sero-
logical surveillance at the local, regional, and na-
tional levels and identifying people who have al-
ready had contact with the virus. Compared to 
molecular assays, these methods save time and 
are simple to perform, playing an essential role in 
large-scale testing to evaluate people’s immunity 
against SARS-CoV2. However, it should be noted 
that there is no certainty whether people having 
antibodies are protected from a second infection.
Some limitations shall be disclosed in this study. 
First, clinical data were not available for all patients 
due to the limited study period. Second, we used 
MAGLUMI 2019-nCoV assay as a reference method 
since no relevant gold standard for serological as-
says is currently validated for comparative studies. 
Finally, another limitation is the lack of estimation 
of the prevalence of the infected population. This 
is due to the severe Coronavirus situation at the 
time of the study. 
In conclusion, our results suggest that the immu-
nochromatographic rapid BIOSYNEX COVID-19 
BSS IgM/IgG test has a good degree of concord-
ance with the MAGLUMI CLIA (IgM and IgG). Thus, 
it might be considered as an efficient additional 
tool for characterizing subjects who have had a 
prior infection and thus developed SARS-CoV-2 
antibodies. 
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